Caribou Biosciences (CRBU) Change in Accured Expenses (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Change in Accured Expenses data on file, last reported at -$2.6 million in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$2.6 million, up 14.67% year-over-year; the trailing twelve-month figure through Mar 2026 was -$5.9 million (down 575.75% YoY), and the FY2025 annual result was -$6.3 million, down 397.09% from the prior year.
• Change in Accured Expenses grew to -$2.6 million in Q1 2026 per CRBU's latest filing, from -$2.8 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $5.0 million in Q2 2024 and troughed at -$4.1 million in Q1 2023.
• A 5-year average of -$74933.3 and a median of -$1.1 million in 2025 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2022 and 2024: Change in Accured Expenses jumped 198.12% in 2022, then sank 176.23% in 2024.
• A 5-year view of Change in Accured Expenses shows it stood at $2.8 million in 2022, then climbed by 2.81% to $2.9 million in 2023, then slumped by 176.23% to -$2.2 million in 2024, then decreased by 27.59% to -$2.8 million in 2025, then climbed by 6.04% to -$2.6 million in 2026.
• Business Quant data shows CRBU's Change in Accured Expenses at -$2.6 million in Q1 2026, -$2.8 million in Q4 2025, and -$1.1 million in Q3 2025.